Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Approval of AUVELITY (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...
The Lancet

Critical care access and outcomes in residents of inpatient-care catchment areas with and without ICUs: a nationwide cohort study in Japan

Nearly half of SMAs lack ICU beds. While post-arrival ICU outcomes were similar, residence in an SMA without ICUs was ...